Soc. Generale Knock-Out GNMSF/ DE000CL7HDE8 /
2024-09-09 8:23:55 AM | Chg.- | Bid9:22:57 AM | Ask9:22:57 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.55EUR | - | 2.82 Bid Size: 4,000 |
2.85 Ask Size: 4,000 |
Genmab A/S | 1,693.4714 - | 2078-12-31 | Call |
GlobeNewswire
08-19
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire
06-28
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021